orforglipron vs Utreglutide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1 receptor · full Obesity pipeline

orforglipron · Foundayo

Marketed by Eli Lilly and partners

Approved in Obesitysmall molecule
Partial signal

NCT05803421 · Phase 3 · completed

ACHIEVE-4 was a randomized, open-label, event-driven Phase 3 trial. It assigned 2,749 adults with type 2 diabetes, obesity or overweight and established cardiovascular or chronic kidney disease to oral orforglipron or injected insulin glargine once daily. The primary endpoint was time to the first major cardiovascular event, and orforglipron had to be shown non-inferior to insulin glargine, with the upper limit of the 95% confidence interval for the hazard ratio below 1.8. Over a median of 2 years, events occurred in 4.2% of orforglipron patients and 5.0% of insulin glargine patients (hazard ratio 0.84, 95% CI 0.59 to 1.20), so non-inferiority was shown and the trial met its primary endpoint. The figures come from the peer-reviewed paper in The Lancet.

Next expected readout: February 2027 · NCT06672549 (registry estimate)

Reported efficacy

Mean Percent Change from Baseline in Body Weight (Baseline, Week 72): Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001) (met)

Result source: NCT05872620

Utreglutide

Developed by Sun Pharmaceutical Industries

Phase 2 in Obesitypeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2027 · NCT07282743 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointorforglipronUtreglutide
Body weight, % change-7.9% vs -0.6%−7.3 vs placebo36 mg QD · wk 72 · n 60NCT05931380
11 other results
  • -8.7% vs -0.6% 12 mg QD · wk 72 · n 57 · Phase 3 · primary NCT05931380
  • -5.9% vs -0.6% 6 mg QD · wk 72 · n 61 · Phase 3 · primary NCT05931380
  • -12.3% vs -2% 36 mg · wk 26 · n 56 · Phase 2 · primary NCT05051579
  • -8.6% vs -2% 12 mg · wk 26 · n 44 · Phase 2 · primary NCT05051579
  • -12.6% vs -2% 45 mg · wk 26 · n 57 · Phase 2 · primary NCT05051579
  • -11.2% vs -2% 24 mg · wk 26 · n 51 · Phase 2 · primary NCT05051579
  • -13.5% vs -2.3% 36 mg · wk 36 · n 56 · Phase 2 · secondary NCT05051579
  • -9.4% vs -2.3% 12 mg · wk 36 · n 44 · Phase 2 · secondary NCT05051579
  • -14.7% vs -2.3% 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • -12.5% vs -2.3% 24 mg · wk 36 · n 51 · Phase 2 · secondary NCT05051579
  • -9.6% vs -2.5% orforglipron 17.2 mg · wk 72 · Phase 3 · primary NCT05872620
—Not reported
Weight loss of 5% or more58.3% vs 15%+43.3 vs placebo36 mg QD · wk 72 · n 60NCT05931380
10 other results
  • 61.4% vs 15% 12 mg QD · wk 72 · n 57 · Phase 3 · primary NCT05931380
  • 45.9% vs 15% 6 mg QD · wk 72 · n 61 · Phase 3 · primary NCT05931380
  • 92.0% vs 24.0% 36 mg · wk 36 · n 56 · Phase 2 · secondary NCT05051579
  • 89.5% vs 22.9% 36 mg · wk 26 · n 56 · Phase 2 · secondary NCT05051579
  • 72% vs 24.0% 12 mg · wk 36 · n 44 · Phase 2 · secondary NCT05051579
  • 74.4% vs 22.9% 12 mg · wk 26 · n 44 · Phase 2 · secondary NCT05051579
  • 90.4% vs 24.0% 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • 87.3% vs 22.9% 45 mg · wk 26 · n 57 · Phase 2 · secondary NCT05051579
  • 89.5% vs 24.0% 24 mg · wk 36 · n 51 · Phase 2 · secondary NCT05051579
  • 88.8% vs 22.9% 24 mg · wk 26 · n 51 · Phase 2 · secondary NCT05051579
—Not reported
Weight loss of 10% or more38.3% vs 3.3%+35 vs placebo36 mg QD · wk 72 · n 60NCT05931380
10 other results
  • 35.1% vs 3.3% 12 mg QD · wk 72 · n 57 · Phase 3 · secondary NCT05931380
  • 18.0% vs 3.3% 6 mg QD · wk 72 · n 61 · Phase 3 · secondary NCT05931380
  • 74.8% vs 8.8% 36 mg · wk 36 · n 56 · Phase 2 · secondary NCT05051579
  • 71.3% vs 2.3% 36 mg · wk 26 · n 56 · Phase 2 · secondary NCT05051579
  • 46.5% vs 8.8% 12 mg · wk 36 · n 44 · Phase 2 · secondary NCT05051579
  • 39.4% vs 2.3% 12 mg · wk 26 · n 44 · Phase 2 · secondary NCT05051579
  • 69.1% vs 8.8% 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • 69.9% vs 2.3% 45 mg · wk 26 · n 57 · Phase 2 · secondary NCT05051579
  • 61.9% vs 8.8% 24 mg · wk 36 · n 51 · Phase 2 · secondary NCT05051579
  • 56.6% vs 2.3% 24 mg · wk 26 · n 51 · Phase 2 · secondary NCT05051579
—Not reported
Waist circumference, change (cm)-5.7 vs -0.1−5.6 vs placebo36 mg QD · wk 72 · n 60NCT05931380
12 other results
  • -5.9 vs -0.1 12 mg QD · wk 72 · n 57 · Phase 3 · secondary NCT05931380
  • -3.7 vs -0.1 6 mg QD · wk 72 · n 61 · Phase 3 · secondary NCT05931380
  • -10.6 vs -4 36 mg · wk 36 · n 52 · Phase 2 · secondary NCT05051579
  • -10.1 vs -3.6 36 mg · wk 26 · n 52 · Phase 2 · secondary NCT05051579
  • -9.6 vs -4 12 mg · wk 36 · n 43 · Phase 2 · secondary NCT05051579
  • -8 vs -3.6 12 mg · wk 26 · n 43 · Phase 2 · secondary NCT05051579
  • -13.6 vs -4 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • -12.2 vs -3.6 45 mg · wk 26 · n 57 · Phase 2 · secondary NCT05051579
  • -11.2 vs -4 24 mg · wk 36 · n 49 · Phase 2 · secondary NCT05051579
  • -8.8 vs -3.6 24 mg · wk 26 · n 49 · Phase 2 · secondary NCT05051579
  • -5.8 n 9 · Phase 1 · secondary NCT06023095
  • -11.7 n 9 · Phase 1 · secondary NCT06023095
—Not reported

Body weight, % change

orforglipron
-7.9% vs -0.6%−7.3 vs placebo36 mg QD · wk 72 · n 60NCT05931380
11 other results
  • -8.7% vs -0.6% 12 mg QD · wk 72 · n 57 · Phase 3 · primary NCT05931380
  • -5.9% vs -0.6% 6 mg QD · wk 72 · n 61 · Phase 3 · primary NCT05931380
  • -12.3% vs -2% 36 mg · wk 26 · n 56 · Phase 2 · primary NCT05051579
  • -8.6% vs -2% 12 mg · wk 26 · n 44 · Phase 2 · primary NCT05051579
  • -12.6% vs -2% 45 mg · wk 26 · n 57 · Phase 2 · primary NCT05051579
  • -11.2% vs -2% 24 mg · wk 26 · n 51 · Phase 2 · primary NCT05051579
  • -13.5% vs -2.3% 36 mg · wk 36 · n 56 · Phase 2 · secondary NCT05051579
  • -9.4% vs -2.3% 12 mg · wk 36 · n 44 · Phase 2 · secondary NCT05051579
  • -14.7% vs -2.3% 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • -12.5% vs -2.3% 24 mg · wk 36 · n 51 · Phase 2 · secondary NCT05051579
  • -9.6% vs -2.5% orforglipron 17.2 mg · wk 72 · Phase 3 · primary NCT05872620
Utreglutide
—Not reported

Weight loss of 5% or more

orforglipron
58.3% vs 15%+43.3 vs placebo36 mg QD · wk 72 · n 60NCT05931380
10 other results
  • 61.4% vs 15% 12 mg QD · wk 72 · n 57 · Phase 3 · primary NCT05931380
  • 45.9% vs 15% 6 mg QD · wk 72 · n 61 · Phase 3 · primary NCT05931380
  • 92.0% vs 24.0% 36 mg · wk 36 · n 56 · Phase 2 · secondary NCT05051579
  • 89.5% vs 22.9% 36 mg · wk 26 · n 56 · Phase 2 · secondary NCT05051579
  • 72% vs 24.0% 12 mg · wk 36 · n 44 · Phase 2 · secondary NCT05051579
  • 74.4% vs 22.9% 12 mg · wk 26 · n 44 · Phase 2 · secondary NCT05051579
  • 90.4% vs 24.0% 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • 87.3% vs 22.9% 45 mg · wk 26 · n 57 · Phase 2 · secondary NCT05051579
  • 89.5% vs 24.0% 24 mg · wk 36 · n 51 · Phase 2 · secondary NCT05051579
  • 88.8% vs 22.9% 24 mg · wk 26 · n 51 · Phase 2 · secondary NCT05051579
Utreglutide
—Not reported

Weight loss of 10% or more

orforglipron
38.3% vs 3.3%+35 vs placebo36 mg QD · wk 72 · n 60NCT05931380
10 other results
  • 35.1% vs 3.3% 12 mg QD · wk 72 · n 57 · Phase 3 · secondary NCT05931380
  • 18.0% vs 3.3% 6 mg QD · wk 72 · n 61 · Phase 3 · secondary NCT05931380
  • 74.8% vs 8.8% 36 mg · wk 36 · n 56 · Phase 2 · secondary NCT05051579
  • 71.3% vs 2.3% 36 mg · wk 26 · n 56 · Phase 2 · secondary NCT05051579
  • 46.5% vs 8.8% 12 mg · wk 36 · n 44 · Phase 2 · secondary NCT05051579
  • 39.4% vs 2.3% 12 mg · wk 26 · n 44 · Phase 2 · secondary NCT05051579
  • 69.1% vs 8.8% 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • 69.9% vs 2.3% 45 mg · wk 26 · n 57 · Phase 2 · secondary NCT05051579
  • 61.9% vs 8.8% 24 mg · wk 36 · n 51 · Phase 2 · secondary NCT05051579
  • 56.6% vs 2.3% 24 mg · wk 26 · n 51 · Phase 2 · secondary NCT05051579
Utreglutide
—Not reported

Waist circumference, change (cm)

orforglipron
-5.7 vs -0.1−5.6 vs placebo36 mg QD · wk 72 · n 60NCT05931380
12 other results
  • -5.9 vs -0.1 12 mg QD · wk 72 · n 57 · Phase 3 · secondary NCT05931380
  • -3.7 vs -0.1 6 mg QD · wk 72 · n 61 · Phase 3 · secondary NCT05931380
  • -10.6 vs -4 36 mg · wk 36 · n 52 · Phase 2 · secondary NCT05051579
  • -10.1 vs -3.6 36 mg · wk 26 · n 52 · Phase 2 · secondary NCT05051579
  • -9.6 vs -4 12 mg · wk 36 · n 43 · Phase 2 · secondary NCT05051579
  • -8 vs -3.6 12 mg · wk 26 · n 43 · Phase 2 · secondary NCT05051579
  • -13.6 vs -4 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • -12.2 vs -3.6 45 mg · wk 26 · n 57 · Phase 2 · secondary NCT05051579
  • -11.2 vs -4 24 mg · wk 36 · n 49 · Phase 2 · secondary NCT05051579
  • -8.8 vs -3.6 24 mg · wk 26 · n 49 · Phase 2 · secondary NCT05051579
  • -5.8 n 9 · Phase 1 · secondary NCT06023095
  • -11.7 n 9 · Phase 1 · secondary NCT06023095
Utreglutide
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Utreglutide: no structured comparison results are available for Obesity.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. orforglipron: 4 of 4 rows · Utreglutide: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricorforglipron
Dropout rate
10%36 mg QDa
NCT05931380 · Phase 3 · registry result, not featured evidence
show 97 more results
8.8%12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
11.5%6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
—36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
12%12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
13.2%24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—17.2 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—36 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—36 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—12 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—12 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—6 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—6 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—24 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—24 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—14.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—9 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—5.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—3 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—3 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—2.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—1 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—1 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—0.8 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 1)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 2)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 3)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 4)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 5)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 6)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 7)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 8)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 9)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 10)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 12)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 13)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 14)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 15)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 16)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 18)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 11)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 17)
NCT06440980 · Phase 1 · registry result, not featured evidence
10%LY3502970 (Cohort 1)
NCT06023095 · Phase 1 · registry result, not featured evidence
10%LY3502970 (Cohort 2)
NCT06023095 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—12 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—12 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—6 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—6 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg + 0.2 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 0.25 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 1000 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 0.25 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—24 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—24 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—20 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—20 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—3 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—3 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—1 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—1 mg + 1000 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—1 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—36 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—36 mg DF capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—36 mg EPB capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—60 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—45 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—37.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—37.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—35 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—35 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—20 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—16 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—10 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—8 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—2.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—2 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—0.8 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%LY3502970 Cohort 1
NCT05313802 · Phase 1 · registry result, not featured evidence
4.2%LY3502970 Cohort 2
NCT05313802 · Phase 1 · registry result, not featured evidence
8.3%LY3502970 Cohort 3
NCT05313802 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
3.3%36 mg QDa
NCT05931380 · Phase 3 · registry result, not featured evidence
show 97 more results
3.5%12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
1.6%6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
—36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
4%12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
1.9%24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—17.2 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—36 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—36 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—12 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—12 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—6 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—6 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—24 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—24 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—14.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—9 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—5.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—3 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—3 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—2.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—1 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—1 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—0.8 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 1)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 2)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 3)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 4)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 5)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 6)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 7)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 8)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 9)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 10)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 12)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 13)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 14)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 15)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 16)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 18)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 11)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 17)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%LY3502970 (Cohort 1)
NCT06023095 · Phase 1 · registry result, not featured evidence
10%LY3502970 (Cohort 2)
NCT06023095 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—12 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—12 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—6 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—6 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg + 0.2 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 0.25 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 1000 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 0.25 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—24 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—24 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—20 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—20 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—3 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—3 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—1 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—1 mg + 1000 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—1 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—36 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—36 mg DF capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—36 mg EPB capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—60 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—45 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—37.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—37.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—35 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—35 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—20 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—16 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—10 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—8 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—2.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—2 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—0.8 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%LY3502970 Cohort 1
NCT05313802 · Phase 1 · registry result, not featured evidence
4.2%LY3502970 Cohort 2
NCT05313802 · Phase 1 · registry result, not featured evidence
4.2%LY3502970 Cohort 3
NCT05313802 · Phase 1 · registry result, not featured evidence
Serious AEs
10%36 mg QDa
NCT05931380 · Phase 3 · registry result, not featured evidence
show 97 more results
5.3%12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
1.6%6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
0%36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
10.3%36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
0%12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
6.5%45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
0%45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
3.8%24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
0%17.2 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%36 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0.6%36 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%12 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%12 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%6 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0.5%6 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%24 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%24 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%14.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%9 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0.5%5.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%3 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%3 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%2.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%1 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%1 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%0.8 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 1)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 2)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 3)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 4)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 5)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 6)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 7)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 8)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 9)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 10)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 12)
NCT06440980 · Phase 1 · registry result, not featured evidence
2%tablet QD (dose level 13)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 14)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 15)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 16)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 18)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 11)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 17)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%LY3502970 (Cohort 1)
NCT06023095 · Phase 1 · registry result, not featured evidence
0%LY3502970 (Cohort 2)
NCT06023095 · Phase 1 · registry result, not featured evidence
0%36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%12 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
5.3%12 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%6 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%6 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg + 0.2 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 0.25 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 1000 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 0.25 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%24 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%24 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%20 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%20 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%3 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%3 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%1 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%1 mg + 1000 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%1 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
2.2%36 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
0%36 mg DF capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
0%36 mg EPB capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
0%60 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%45 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%37.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%37.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%35 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%35 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
2.2%20 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%16 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
0%10 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%8 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
0%5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%2.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%2 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
0%0.8 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%LY3502970 Cohort 1
NCT05313802 · Phase 1 · registry result, not featured evidence
0%LY3502970 Cohort 2
NCT05313802 · Phase 1 · registry result, not featured evidence
0%LY3502970 Cohort 3
NCT05313802 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
36 mg QDa
nausea 33.3% (placebo 0%)
constipation 31.7% (placebo 8.3%)
nasopharyngitis 20% (placebo 35%)
NCT05931380 · Phase 3 · registry result, not featured evidence
show 97 more results
12 mg QD
nasopharyngitis 42.1% (placebo 35%)
constipation 28.1% (placebo 8.3%)
nausea 15.8% (placebo 0%)
NCT05931380 · Phase 3 · registry result, not featured evidence
6 mg QD
constipation 36.1% (placebo 8.3%)
nasopharyngitis 26.2% (placebo 35%)
diarrhoea 14.8% (placebo 3.3%)
NCT05931380 · Phase 3 · registry result, not featured evidence
36 mg
nausea 41.4% (placebo 10%)
constipation 27.6% (placebo 6%)
vomiting 27.6% (placebo 6%)
NCT05051579 · Phase 2 · registry result, not featured evidence
36 mg
nausea 48.3% (placebo 10%)
constipation 24.1% (placebo 6%)
covid-19 24.1% (placebo 18%)
NCT05051579 · Phase 2 · registry result, not featured evidence
12 mg
nausea 50% (placebo 10%)
vomiting 26% (placebo 6%)
constipation 24% (placebo 6%)
NCT05051579 · Phase 2 · registry result, not featured evidence
45 mg
nausea 41.9% (placebo 10%)
vomiting 29% (placebo 6%)
constipation 19.4% (placebo 6%)
NCT05051579 · Phase 2 · registry result, not featured evidence
45 mg
nausea 36.7% (placebo 10%)
diarrhoea 33.3% (placebo 10%)
vomiting 26.7% (placebo 6%)
NCT05051579 · Phase 2 · registry result, not featured evidence
24 mg
nausea 58.5% (placebo 10%)
diarrhoea 35.8% (placebo 10%)
constipation 32.1% (placebo 6%)
NCT05051579 · Phase 2 · registry result, not featured evidence
17.2 mg tablet QD
vomiting 5.7%
headache 3.4%
nausea 3.4%
NCT06440980 · Phase 1 · registry result, not featured evidence
36 mg capsule QD
headache 6.7%
constipation 4.4%
dizziness 4.4%
NCT06440980 · Phase 1 · registry result, not featured evidence
36 mg capsule QD
headache 15.9%
vomiting 10.8%
diarrhoea 6.3%
NCT06440980 · Phase 1 · registry result, not featured evidence
12 mg capsule QD
constipation 6%
nausea 6%
headache 4%
NCT06440980 · Phase 1 · registry result, not featured evidence
12 mg capsule QD
constipation 21%
headache 19.4%
nausea 17.2%
NCT06440980 · Phase 1 · registry result, not featured evidence
6 mg capsule QD
headache 8.7%
dyspepsia 4.3%
vomiting 4.3%
NCT06440980 · Phase 1 · registry result, not featured evidence
6 mg capsule QD
headache 12.3%
nausea 9.4%
dyspepsia 7.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
24 mg capsule QD
headache 10%
vomiting 6%
abdominal pain 4%
NCT06440980 · Phase 1 · registry result, not featured evidence
24 mg capsule QD
nausea 17.1%
diarrhoea 12.7%
constipation 10.5%
NCT06440980 · Phase 1 · registry result, not featured evidence
14.5 mg tablet QD
headache 8.3%
nausea 8.3%
diarrhoea 6.7%
NCT06440980 · Phase 1 · registry result, not featured evidence
9 mg tablet QD
headache 9.7%
constipation 9.1%
vomiting 8.1%
NCT06440980 · Phase 1 · registry result, not featured evidence
5.5 mg tablet QD
headache 8.4%
nausea 8.4%
constipation 4.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
3 mg capsule QD
nausea 4.3%
decreased appetite 2.1%
diarrhoea 2.1%
NCT06440980 · Phase 1 · registry result, not featured evidence
3 mg capsule QD
headache 17.6%
nausea 13.8%
constipation 9.5%
NCT06440980 · Phase 1 · registry result, not featured evidence
2.5 mg tablet QD
headache 8.1%
constipation 6.2%
nausea 6.2%
NCT06440980 · Phase 1 · registry result, not featured evidence
1 mg capsule QD
constipation 7.7%
decreased appetite 1.9%
eructation 1.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
1 mg capsule QD
constipation 27%
headache 15.8%
nausea 6%
NCT06440980 · Phase 1 · registry result, not featured evidence
0.8 mg tablet QD
constipation 8.9%
headache 8.9%
dyspepsia 4.7%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 1)
constipation 9.6%
diarrhoea 1.9%
eructation 1.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 2)
abdominal pain 3.8%
diarrhoea 3.8%
constipation 1.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 3)
constipation 13.5%
abdominal distension 1.9%
dizziness 1.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 4)
nausea 7.8%
vomiting 7.8%
constipation 5.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 5)
nausea 8.3%
dyspepsia 6.3%
headache 6.3%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 6)
diarrhoea 5.9%
abdominal pain 3.9%
constipation 3.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 7)
nausea 6.5%
dyspepsia 4.3%
headache 4.3%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 8)
dyspepsia 6.4%
headache 4.3%
nausea 4.3%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 9)
nausea 10.9%
abdominal distension 6.5%
abdominal pain 6.5%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 10)
constipation 8%
diarrhoea 6%
dyspepsia 6%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 12)
nausea 8%
headache 6%
diarrhoea 4%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 13)
constipation 8.2%
abdominal pain 4.1%
diarrhoea 4.1%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 14)
dizziness 12.2%
headache 6.1%
abdominal pain 4.1%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 15)
nausea 8%
constipation 4%
diarrhoea 4%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 16)
heart rate increased 8.9%
constipation 4.4%
headache 4.4%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 18)
constipation 6.7%
diarrhoea 6.7%
nausea 4.4%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 11)
dyspepsia 6%
constipation 4%
diarrhoea 4%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 17)
nausea 13.3%
headache 6.7%
diarrhoea 4.4%
NCT06440980 · Phase 1 · registry result, not featured evidence
decreased appetite 70% (placebo 50%)
diarrhoea 60% (placebo 25%)
eructation 40% (placebo 0%)
NCT06023095 · Phase 1 · registry result, not featured evidence
nausea 80% (placebo 0%)
decreased appetite 70% (placebo 50%)
diarrhoea 70% (placebo 25%)
NCT06023095 · Phase 1 · registry result, not featured evidence
36 mg
constipation 4.5%
diarrhoea 4.5%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg
abdominal pain upper 4.5%
dizziness 4.5%
vomiting 4.5%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg
abdominal pain 0%
abdominal pain upper 0%
alanine aminotransferase increased 0%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg QD
back pain 4.5%
diarrhoea 4.5%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg QD
constipation 23.1%
nausea 11.5%
abdominal pain 7.7%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg
abdominal pain 0%
abdominal pain upper 0%
alanine aminotransferase increased 0%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg QD
constipation 22.2%
alopecia 5.6%
diarrhoea 5.6%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg QD
anxiety 6.3%
constipation 6.3%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence
12 mg QD
alanine aminotransferase increased 3.8%
aspartate aminotransferase increased 3.8%
fatigue 3.8%
NCT06186622 · Phase 1 · registry result, not featured evidence
12 mg QD
back pain 5.3%
constipation 5.3%
cough 5.3%
NCT06186622 · Phase 1 · registry result, not featured evidence
6 mg QD
dyspepsia 7.7%
nausea 7.7%
diarrhoea 3.8%
NCT06186622 · Phase 1 · registry result, not featured evidence
6 mg QD
fatigue 15.8%
eructation 10.5%
headache 10.5%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg + 0.2 mg
dizziness 4.8%
headache 4.8%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 0.25 mg
nausea 9.1%
abdominal pain 0%
abdominal pain upper 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 20 mg
decreased appetite 4.5%
headache 4.5%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 20 mg
abdominal pain 0%
abdominal pain upper 0%
alanine aminotransferase increased 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 1000 mg
headache 4.5%
nausea 4.5%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 20 mg
abdominal pain 0%
abdominal pain upper 0%
alanine aminotransferase increased 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 0.25 mg
constipation 6.3%
abdominal pain 0%
abdominal pain upper 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 20 mg
abdominal pain upper 6.3%
abdominal pain 0%
alanine aminotransferase increased 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 20 mg
dysmenorrhoea 6.3%
abdominal pain 0%
abdominal pain upper 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
24 mg QD
abdominal pain 3.8%
diarrhoea 3.8%
headache 3.8%
NCT06186622 · Phase 1 · registry result, not featured evidence
24 mg QD
constipation 5.6%
diarrhoea 5.6%
eructation 5.6%
NCT06186622 · Phase 1 · registry result, not featured evidence
20 mg + 20 mg
alanine aminotransferase increased 9.1%
aspartate aminotransferase increased 9.1%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
20 mg + 20 mg
alanine aminotransferase increased 12.5%
aspartate aminotransferase increased 12.5%
headache 6.3%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
3 mg QD
diarrhoea 3.8%
fatigue 3.8%
nausea 3.8%
NCT06186622 · Phase 1 · registry result, not featured evidence
3 mg QD
abdominal pain 10%
nausea 10%
alanine aminotransferase increased 5%
NCT06186622 · Phase 1 · registry result, not featured evidence
1 mg QD
medication error 7.4%
dysmenorrhoea 3.7%
fatigue 3.7%
NCT06186622 · Phase 1 · registry result, not featured evidence
1 mg + 1000 mg
headache 3.7%
abdominal pain 0%
abdominal pain upper 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
1 mg QD
eructation 15%
decreased appetite 10%
headache 10%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg capsule
nausea 9.5%
abdominal pain 4.8%
constipation 4.8%
NCT05841238 · Phase 1 · registry result, not featured evidence
36 mg capsule
diarrhoea 4.4%
abdominal pain 2.2%
abdominal distension 0%
NCT05841238 · Phase 1 · registry result, not featured evidence
36 mg DF capsule
constipation 8.3%
diarrhoea 8.3%
nausea 8.3%
NCT05841238 · Phase 1 · registry result, not featured evidence
36 mg EPB capsule
nausea 41.7%
headache 16.7%
diarrhoea 8.3%
NCT05841238 · Phase 1 · registry result, not featured evidence
60 mg tablet
vomiting 14.3%
constipation 4.8%
dyspepsia 4.8%
NCT05841238 · Phase 1 · registry result, not featured evidence
45 mg tablet
abdominal distension 9.5%
nausea 9.5%
vomiting 4.8%
NCT05841238 · Phase 1 · registry result, not featured evidence
37.5 mg tablet
headache 19%
nausea 19%
constipation 9.5%
NCT05841238 · Phase 1 · registry result, not featured evidence
37.5 mg tablet
nausea 14.6%
headache 12.2%
vomiting 12.2%
NCT05841238 · Phase 1 · registry result, not featured evidence
35 mg tablet
dyspepsia 14.3%
flatulence 14.3%
nausea 14.3%
NCT05841238 · Phase 1 · registry result, not featured evidence
35 mg tablet
intertrigo 14.3%
abdominal distension 0%
abdominal pain 0%
NCT05841238 · Phase 1 · registry result, not featured evidence
20 mg tablet
dyspepsia 4.3%
abdominal pain 2.2%
diarrhoea 2.2%
NCT05841238 · Phase 1 · registry result, not featured evidence
16 mg capsule
diarrhoea 6.5%
vomiting 2.2%
abdominal distension 0%
NCT05841238 · Phase 1 · registry result, not featured evidence
10 mg tablet
constipation 12.2%
nausea 4.1%
dyspepsia 2%
NCT05841238 · Phase 1 · registry result, not featured evidence
8 mg capsule
dyspepsia 10.2%
decreased appetite 6.1%
diarrhoea 6.1%
NCT05841238 · Phase 1 · registry result, not featured evidence
5 mg tablet
headache 12%
dyspepsia 4%
abdominal pain 2%
NCT05841238 · Phase 1 · registry result, not featured evidence
2.5 mg tablet
headache 4%
decreased appetite 2%
gastrooesophageal reflux disease 2%
NCT05841238 · Phase 1 · registry result, not featured evidence
2 mg capsule
constipation 10%
diarrhoea 2%
abdominal distension 0%
NCT05841238 · Phase 1 · registry result, not featured evidence
0.8 mg tablet
constipation 3.8%
headache 3.8%
nausea 3.8%
NCT05841238 · Phase 1 · registry result, not featured evidence
constipation 37.5%
headache 33.3%
weight decreased 25%
NCT05313802 · Phase 1 · registry result, not featured evidence
dyspepsia 41.7%
constipation 33.3%
weight decreased 29.2%
NCT05313802 · Phase 1 · registry result, not featured evidence
constipation 25%
dyspepsia 25%
headache 16.7%
NCT05313802 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

orforglipron

Weight -9.6% vs -2.5% placebo @ 72wkorforglipron 17.2 mg
percent change · % of baseline
NCT05872620 · Phase 3 · sponsor-reported, not registry data
show 11 more results
-7.93% (n=60) vs -0.63% (n=60) placebo @ 72wk36 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-12.3% (n=56) vs -2% (n=48) placebo @ 26wk36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-13.5% (n=56) vs -2.3% (n=48) placebo @ 36wk36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-8.69% (n=57) vs -0.63% (n=60) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-8.6% (n=44) vs -2% (n=48) placebo @ 26wk12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-9.4% (n=44) vs -2.3% (n=48) placebo @ 36wk12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-5.9% (n=61) vs -0.63% (n=60) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-12.6% (n=57) vs -2% (n=48) placebo @ 26wk45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-14.7% (n=57) vs -2.3% (n=48) placebo @ 36wk45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-11.2% (n=51) vs -2% (n=48) placebo @ 26wk24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-12.5% (n=51) vs -2.3% (n=48) placebo @ 36wk24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
Weight Loss 5% 58.33% (n=60) vs 15% (n=60) placebo @ 72wk36 mg QD
responder rate · % of participants
NCT05931380 · Phase 3 · registry result, not featured evidence
show 10 more results
89.46% (n=56) vs 22.88% (n=48) placebo @ 26wk36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
92.05% (n=56) vs 24.02% (n=48) placebo @ 36wk36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
61.4% (n=57) vs 15% (n=60) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
74.39% (n=44) vs 22.88% (n=48) placebo @ 26wk12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
72% (n=44) vs 24.02% (n=48) placebo @ 36wk12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
45.9% (n=61) vs 15% (n=60) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
87.26% (n=57) vs 22.88% (n=48) placebo @ 26wk45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
90.44% (n=57) vs 24.02% (n=48) placebo @ 36wk45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
88.84% (n=51) vs 22.88% (n=48) placebo @ 26wk24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
89.47% (n=51) vs 24.02% (n=48) placebo @ 36wk24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
Weight Loss 10% 38.33% (n=60) vs 3.33% (n=60) placebo @ 72wk36 mg QD
responder rate · % of participants
NCT05931380 · Phase 3 · registry result, not featured evidence
show 10 more results
71.3% (n=56) vs 2.25% (n=48) placebo @ 26wk36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
74.75% (n=56) vs 8.85% (n=48) placebo @ 36wk36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
35.09% (n=57) vs 3.33% (n=60) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
39.39% (n=44) vs 2.25% (n=48) placebo @ 26wk12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
46.5% (n=44) vs 8.85% (n=48) placebo @ 36wk12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
18.03% (n=61) vs 3.33% (n=60) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
69.86% (n=57) vs 2.25% (n=48) placebo @ 26wk45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
69.07% (n=57) vs 8.85% (n=48) placebo @ 36wk45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
56.61% (n=51) vs 2.25% (n=48) placebo @ 26wk24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
61.88% (n=51) vs 8.85% (n=48) placebo @ 36wk24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
Weight Loss 15% 18.33% (n=60) vs 0% (n=60) placebo @ 72wk36 mg QD
responder rate · % of participants
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
22.81% (n=57) vs 0% (n=60) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
9.84% (n=61) vs 0% (n=60) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
Weight Loss 20% 8.33% (n=60) vs 0% (n=60) placebo @ 72wk36 mg QD
responder rate · % of participants
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
12.28% (n=57) vs 0% (n=60) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
3.28% (n=61) vs 0% (n=60) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
BMI -2.63 vs -0.21 placebo kg @ 72wk36 mg QD
absolute change · kg
NCT05931380 · Phase 3 · registry result, not featured evidence
show 12 more results
-4.6 vs -0.8 placebo kg @ 26wk36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-5 vs -0.9 placebo kg @ 36wk36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-2.83 vs -0.21 placebo kg @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-3.2 vs -0.8 placebo kg @ 26wk12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-3.4 vs -0.9 placebo kg @ 36wk12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-1.94 vs -0.21 placebo kg @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-4.7 vs -0.8 placebo kg @ 26wk45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-5.5 vs -0.9 placebo kg @ 36wk45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-4.2 vs -0.8 placebo kg @ 26wk24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-4.7 vs -0.9 placebo kg @ 36wk24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-2.3046 vs NA placebo kg
NCT06023095 · Phase 1 · registry result, not featured evidence
-3.5964 vs NA placebo kg
NCT06023095 · Phase 1 · registry result, not featured evidence
HbA1c Less Than 6 5 78.57% (n=14) vs 0% (n=14) placebo @ 72wk36 mg QD
responder rate · % of participants
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
45.45% (n=11) vs 0% (n=14) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
31.25% (n=16) vs 0% (n=14) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
VAT Change Cm2 -49.3 vs -7.2 placebo cm @ 72wk36 mg QD
absolute change · cm
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
-52.3 vs -7.2 placebo cm @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-47.5 vs -7.2 placebo cm @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
Waist Circumference Change -5.67 vs -0.063 placebo cm @ 72wk36 mg QD
absolute change · cm
NCT05931380 · Phase 3 · registry result, not featured evidence
show 12 more results
-10.1 vs -3.6 placebo cm @ 26wk36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-10.6 vs -4 placebo cm @ 36wk36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-5.87 vs -0.063 placebo cm @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-8 vs -3.6 placebo cm @ 26wk12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-9.6 vs -4 placebo cm @ 36wk12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-3.67 vs -0.063 placebo cm @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-12.2 vs -3.6 placebo cm @ 26wk45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-13.6 vs -4 placebo cm @ 36wk45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-8.8 vs -3.6 placebo cm @ 26wk24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-11.2 vs -4 placebo cm @ 36wk24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-5.778 vs NA placebo cm
NCT06023095 · Phase 1 · registry result, not featured evidence
-11.667 vs NA placebo cm
NCT06023095 · Phase 1 · registry result, not featured evidence
SBP -4.36 vs -0.055 placebo mmHg @ 72wk36 mg QD
absolute change · mmHg
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
-3.84 vs -0.055 placebo mmHg @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-5.08 vs -0.055 placebo mmHg @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
Non-HDL-C -10.75% (n=60) vs 0.05% (n=60) placebo @ 72wk36 mg QD
percent change · % of baseline
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
-10.2% (n=57) vs 0.05% (n=60) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-6.91% (n=61) vs 0.05% (n=60) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
HDL-C 5.17% (n=60) vs 7.37% (n=60) placebo @ 72wk36 mg QD
percent change · % of baseline
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
8.62% (n=57) vs 7.37% (n=60) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
5.75% (n=61) vs 7.37% (n=60) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence

+ 8 further endpoints in the CSV export.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

orforglipron · Foundayo

Marketed by Eli Lilly and partners

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT05803421 · Phase 3 · completed

ACHIEVE-4 was a randomized, open-label, event-driven Phase 3 trial. It assigned 2,749 adults with type 2 diabetes, obesity or overweight and established cardiovascular or chronic kidney disease to oral orforglipron or injected insulin glargine once daily. The primary endpoint was time to the first major cardiovascular event, and orforglipron had to be shown non-inferior to insulin glargine, with the upper limit of the 95% confidence interval for the hazard ratio below 1.8. Over a median of 2 years, events occurred in 4.2% of orforglipron patients and 5.0% of insulin glargine patients (hazard ratio 0.84, 95% CI 0.59 to 1.20), so non-inferiority was shown and the trial met its primary endpoint. The figures come from the peer-reviewed paper in The Lancet.

Next expected readout: May 2027 · NCT07613307 (registry estimate)

Reported efficacy

Mean Percent Change from Baseline in Body Weight (Baseline, Week 72): Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001) (met)

Result source: NCT05872620

Utreglutide

Developed by Sun Pharmaceutical Industries

Phase 2 in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2027 · NCT07282743 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointorforglipronUtreglutide
HbA1c, change-1.4% vs -0.1%−1.3 vs placebo36 mg · wk 40 · n 141NCT05971940
14 other results
  • -1.6% vs -0.1% 12 mg · wk 40 · n 137 · Phase 3 · primary NCT05971940
  • -1.3% vs -0.1% 3 mg · wk 40 · n 143 · Phase 3 · primary NCT05971940
  • -2.0% vs -0.4% 36 mg · wk 26 · n 57 · Phase 2 · primary NCT05048719
  • -1.9% vs -0.4% 12 mg · wk 26 · n 49 · Phase 2 · primary NCT05048719
  • -1.2% vs -0.4% 3 mg · wk 26 · n 46 · Phase 2 · primary NCT05048719
  • -2.1% vs -0.4% 45 mg · wk 26 · n 58 · Phase 2 · primary NCT05048719
  • -1.8% vs -0.4% 24 mg · wk 26 · n 42 · Phase 2 · primary NCT05048719
  • -2.0% vs -1.1% 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • -1.9% vs -1.1% 12 mg · wk 26 · n 49 · Phase 2 · secondary NCT05048719
  • -1.2% vs -1.1% 3 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
  • -2.1% vs -1.1% 45 mg · wk 26 · n 58 · Phase 2 · secondary NCT05048719
  • -1.8% vs -1.1% 24 mg · wk 26 · n 42 · Phase 2 · secondary NCT05048719
  • -1.7% vs -0.5% orforglipron 17.2 mg · wk 72 · Phase 3 · primary NCT05872620
  • 1.7% vs 0.8% wk 40 · Phase 3 · primary NCT06192108
—Not reported
Body weight, change (kg)-7.3 vs -1.3−6 vs placebo36 mg · wk 40 · n 141NCT05971940
7 other results
  • -5.5 vs -1.3 12 mg · wk 40 · n 137 · Phase 3 · secondary NCT05971940
  • -4.4 vs -1.3 3 mg · wk 40 · n 143 · Phase 3 · secondary NCT05971940
  • -9.5 vs -2.2 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • -6.5 vs -2.2 12 mg · wk 26 · n 53 · Phase 2 · secondary NCT05048719
  • -3.7 vs -2.2 3 mg · wk 26 · n 50 · Phase 2 · secondary NCT05048719
  • -10.1 vs -2.2 45 mg · wk 26 · n 62 · Phase 2 · secondary NCT05048719
  • -9.7 vs -2.2 24 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
—Not reported
HbA1c below 7%79.0% vs 37.1%+41.9 vs placebo36 mg · wk 40 · n 119NCT05971940
7 other results
  • 81.3% vs 37.1% 12 mg · wk 40 · n 112 · Phase 3 · secondary NCT05971940
  • 78.2% vs 37.1% 3 mg · wk 40 · n 119 · Phase 3 · secondary NCT05971940
  • 92.8% vs 24.3% 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • 78.9% vs 24.3% 12 mg · wk 26 · n 49 · Phase 2 · secondary NCT05048719
  • 65.2% vs 24.3% 3 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
  • 95.8% vs 24.3% 45 mg · wk 26 · n 58 · Phase 2 · secondary NCT05048719
  • 91.2% vs 24.3% 24 mg · wk 26 · n 42 · Phase 2 · secondary NCT05048719
—Not reported
Fasting plasma glucose, change-2.0 vs -1.1−0.9 vs placebo3/6/12/21 mg QD · wk 12 · n 7NCT04426474
4 other results
  • -3 vs -1.1 3/6/9 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
  • -2.9 vs -1.1 3/6/12/15 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
  • -2.4 vs -1.1 3/6/12/21/27 mg QD · wk 12 · n 8 · Phase 1 · secondary NCT04426474
  • -2.3 vs -1.1 3/6/9/21/36/45 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
—Not reported
3-point MACE (% with event)—Not posted · NCT05803421—Not reported

HbA1c, change

orforglipron
-1.4% vs -0.1%−1.3 vs placebo36 mg · wk 40 · n 141NCT05971940
14 other results
  • -1.6% vs -0.1% 12 mg · wk 40 · n 137 · Phase 3 · primary NCT05971940
  • -1.3% vs -0.1% 3 mg · wk 40 · n 143 · Phase 3 · primary NCT05971940
  • -2.0% vs -0.4% 36 mg · wk 26 · n 57 · Phase 2 · primary NCT05048719
  • -1.9% vs -0.4% 12 mg · wk 26 · n 49 · Phase 2 · primary NCT05048719
  • -1.2% vs -0.4% 3 mg · wk 26 · n 46 · Phase 2 · primary NCT05048719
  • -2.1% vs -0.4% 45 mg · wk 26 · n 58 · Phase 2 · primary NCT05048719
  • -1.8% vs -0.4% 24 mg · wk 26 · n 42 · Phase 2 · primary NCT05048719
  • -2.0% vs -1.1% 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • -1.9% vs -1.1% 12 mg · wk 26 · n 49 · Phase 2 · secondary NCT05048719
  • -1.2% vs -1.1% 3 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
  • -2.1% vs -1.1% 45 mg · wk 26 · n 58 · Phase 2 · secondary NCT05048719
  • -1.8% vs -1.1% 24 mg · wk 26 · n 42 · Phase 2 · secondary NCT05048719
  • -1.7% vs -0.5% orforglipron 17.2 mg · wk 72 · Phase 3 · primary NCT05872620
  • 1.7% vs 0.8% wk 40 · Phase 3 · primary NCT06192108
Utreglutide
—Not reported

Body weight, change (kg)

orforglipron
-7.3 vs -1.3−6 vs placebo36 mg · wk 40 · n 141NCT05971940
7 other results
  • -5.5 vs -1.3 12 mg · wk 40 · n 137 · Phase 3 · secondary NCT05971940
  • -4.4 vs -1.3 3 mg · wk 40 · n 143 · Phase 3 · secondary NCT05971940
  • -9.5 vs -2.2 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • -6.5 vs -2.2 12 mg · wk 26 · n 53 · Phase 2 · secondary NCT05048719
  • -3.7 vs -2.2 3 mg · wk 26 · n 50 · Phase 2 · secondary NCT05048719
  • -10.1 vs -2.2 45 mg · wk 26 · n 62 · Phase 2 · secondary NCT05048719
  • -9.7 vs -2.2 24 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
Utreglutide
—Not reported

HbA1c below 7%

orforglipron
79.0% vs 37.1%+41.9 vs placebo36 mg · wk 40 · n 119NCT05971940
7 other results
  • 81.3% vs 37.1% 12 mg · wk 40 · n 112 · Phase 3 · secondary NCT05971940
  • 78.2% vs 37.1% 3 mg · wk 40 · n 119 · Phase 3 · secondary NCT05971940
  • 92.8% vs 24.3% 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • 78.9% vs 24.3% 12 mg · wk 26 · n 49 · Phase 2 · secondary NCT05048719
  • 65.2% vs 24.3% 3 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
  • 95.8% vs 24.3% 45 mg · wk 26 · n 58 · Phase 2 · secondary NCT05048719
  • 91.2% vs 24.3% 24 mg · wk 26 · n 42 · Phase 2 · secondary NCT05048719
Utreglutide
—Not reported

Fasting plasma glucose, change

orforglipron
-2.0 vs -1.1−0.9 vs placebo3/6/12/21 mg QD · wk 12 · n 7NCT04426474
4 other results
  • -3 vs -1.1 3/6/9 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
  • -2.9 vs -1.1 3/6/12/15 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
  • -2.4 vs -1.1 3/6/12/21/27 mg QD · wk 12 · n 8 · Phase 1 · secondary NCT04426474
  • -2.3 vs -1.1 3/6/9/21/36/45 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
Utreglutide
—Not reported

3-point MACE (% with event)

orforglipron
—Not posted · NCT05803421
Utreglutide
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Utreglutide: no structured comparison results are available for Type 2 Diabetes.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. orforglipron: 4 of 4 rows · Utreglutide: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricorforglipron
Dropout rate
6.7%36 mga
NCT06010004 · Phase 3 · registry result, not featured evidence
show 19 more results
5.2%12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
5.3%3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
3.5%36 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
8.8%12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
6.3%3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
7.4%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
11.8%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
10.7%12 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
7.8%3 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
6.5%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
9.4%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
10.6%24 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
—3 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
—2 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
10%3/6/12/15 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
57.1%3/6/12/21 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
11.1%3/6/12/21/27 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9/21/36/45 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
2.2%36 mga
NCT06010004 · Phase 3 · registry result, not featured evidence
show 19 more results
4.4%12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
1.5%3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
1.4%36 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
0%12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
0.7%3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
3.7%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
3.6%12 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
2%3 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%24 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
—3 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
—2 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
10%3/6/12/15 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
35.7%3/6/12/21 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
11.1%3/6/12/21/27 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9/21/36/45 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
Serious AEs
4.5%36 mga
NCT06010004 · Phase 3 · registry result, not featured evidence
show 19 more results
2.2%12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
3%3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
2.8%36 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
5.1%12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
5.6%3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
3.7%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
2.9%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
1.8%12 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
5.9%3 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
3.1%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
10.6%24 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%3 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
0%2 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
0%3/6/12/15 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/12/21 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/12/21/27 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9/21/36/45 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
36 mga
constipation 29.1%
nausea 27.6%
nasopharyngitis 16.4%
NCT06010004 · Phase 3 · registry result, not featured evidence
show 19 more results
12 mg
constipation 30.4%
nasopharyngitis 22.2%
nausea 19.3%
NCT06010004 · Phase 3 · registry result, not featured evidence
3 mg
nasopharyngitis 17.4%
constipation 16.7%
nausea 12.9%
NCT06010004 · Phase 3 · registry result, not featured evidence
36 mg
diarrhoea 25.5% (placebo 9.4%)
diabetic retinopathy 17% (placebo 15.2%)
nausea 17% (placebo 2.2%)
NCT05971940 · Phase 3 · registry result, not featured evidence
12 mg
diarrhoea 21.2% (placebo 9.4%)
dyspepsia 21.2% (placebo 7.2%)
nausea 19% (placebo 2.2%)
NCT05971940 · Phase 3 · registry result, not featured evidence
3 mg
diarrhoea 18.9% (placebo 9.4%)
diabetic retinopathy 14.7% (placebo 15.2%)
nausea 12.6% (placebo 2.2%)
NCT05971940 · Phase 3 · registry result, not featured evidence
36 mg
nausea 37% (placebo 5.5%)
vomiting 33.3% (placebo 1.8%)
diarrhoea 25.9% (placebo 7.3%)
NCT05048719 · Phase 2 · registry result, not featured evidence
36 mg
nausea 26.5% (placebo 5.5%)
vomiting 20.6% (placebo 1.8%)
eructation 8.8% (placebo 0%)
NCT05048719 · Phase 2 · registry result, not featured evidence
12 mg
nausea 37.5% (placebo 5.5%)
vomiting 21.4% (placebo 1.8%)
diarrhoea 16.1% (placebo 7.3%)
NCT05048719 · Phase 2 · registry result, not featured evidence
3 mg
nausea 23.5% (placebo 5.5%)
diarrhoea 21.6% (placebo 7.3%)
constipation 13.7% (placebo 1.8%)
NCT05048719 · Phase 2 · registry result, not featured evidence
45 mg
vomiting 35.5% (placebo 1.8%)
diarrhoea 29% (placebo 7.3%)
nausea 29% (placebo 5.5%)
NCT05048719 · Phase 2 · registry result, not featured evidence
45 mg
diarrhoea 28.1% (placebo 7.3%)
nausea 25% (placebo 5.5%)
vomiting 21.9% (placebo 1.8%)
NCT05048719 · Phase 2 · registry result, not featured evidence
24 mg
nausea 34% (placebo 5.5%)
vomiting 27.7% (placebo 1.8%)
diarrhoea 14.9% (placebo 7.3%)
NCT05048719 · Phase 2 · registry result, not featured evidence
3 mg
nausea 55.6% (placebo 25%)
constipation 33.3% (placebo 0%)
vomiting 22.2% (placebo 25%)
NCT05086445 · Phase 1 · registry result, not featured evidence
2 mg
vomiting 40% (placebo 25%)
nausea 30% (placebo 25%)
abdominal distension 20% (placebo 0%)
NCT05086445 · Phase 1 · registry result, not featured evidence
3/6/12/15 mg QD
nausea 50% (placebo 5.9%)
vomiting 50% (placebo 0%)
decreased appetite 40% (placebo 11.8%)
NCT04426474 · Phase 1 · registry result, not featured evidence
3/6/12/21 mg QD
nausea 42.9% (placebo 5.9%)
decreased appetite 28.6% (placebo 11.8%)
covid-19 21.4% (placebo 5.9%)
NCT04426474 · Phase 1 · registry result, not featured evidence
3/6/12/21/27 mg QD
decreased appetite 55.6% (placebo 11.8%)
vomiting 55.6% (placebo 0%)
nausea 33.3% (placebo 5.9%)
NCT04426474 · Phase 1 · registry result, not featured evidence
3/6/9 mg QD
vomiting 55.6% (placebo 0%)
decreased appetite 44.4% (placebo 11.8%)
nausea 44.4% (placebo 5.9%)
NCT04426474 · Phase 1 · registry result, not featured evidence
3/6/9/21/36/45 mg QD
nausea 77.8% (placebo 5.9%)
decreased appetite 66.7% (placebo 11.8%)
vomiting 55.6% (placebo 0%)
NCT04426474 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

orforglipron

HbA1c -2.13% (n=125) @ 52wk36 mg
absolute change · percentage points
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
-1.97% (n=128) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-1.71% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7% 90.82% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
86.11% (n=128) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
82.73% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 84.56% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
76.23% (n=128) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
62.64% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 5 7 30.51% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
21.92% (n=128) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
7.7% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Fasting Serum Glucose Change mg/dL -64.5 mg @ 52wk36 mg
absolute change · mg
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
-55.1 mg @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-51.7 mg @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Weight -6.75 kg @ 52wk36 mg
absolute change · kg
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
-5.08 kg @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-1.81 kg @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Weight Loss 5% 65.14% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
49.52% (n=127) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
27% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Weight Loss 10% 37.91% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
24.68% (n=127) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
10.11% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Weight Loss 15% 20.94% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
13.96% (n=127) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
2.79% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Waist Circumference Change -6.5 cm @ 52wk36 mg
absolute change · cm
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
-4.6 cm @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-2.4 cm @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
BMI -2.5 kg @ 52wk36 mg
absolute change · kg
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
-1.9 kg @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-0.7 kg @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
SMBG Daily Average Change mg/dL -82.27 mg/dL @ 52wk36 mg
absolute change · mg/dL
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
-73.14 mg/dL @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-66.32 mg/dL @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence

+ 14 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: orforglipron's landscape · Utreglutide's landscape